{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:31Z","timestamp":1794565351576,"version":"4.9.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Advancements in genomics are transforming the clinical management of chronic myeloid leukemia (CML) toward precision medicine. The impact of somatic mutations on treatment outcomes is still under debate. We studied the association of somatic mutations in epigenetic modifier genes and activated signaling\/myeloid transcription factors (AS\/MTFs) with disease progression and treatment failure in patients with CML after tyrosine kinase inhibitor (TKI) therapy. A total of 394 CML samples were sequenced, including 254 samples collected at initial diagnosis and 140 samples taken during follow-up. Single-molecule molecular inversion probe (smMIP)\u2013based next-generation sequencing (NGS) was conducted targeting recurrently mutated loci in 40 genes, with a limit of detection of 0.2%. Seventy mutations were detected in 57 diagnostic samples (22.4%), whereas 64 mutations were detected in 39 of the follow-up samples (27.9%). Carrying any mutation at initial diagnosis was associated with worse outcomes after TKI therapy, particularly in AS\/MTF genes. Patients having these mutations at initial diagnosis and treated with imatinib showed higher risks of treatment failure (hazard ratio, 2.53; 95% confidence interval, 1.13-5.66; P\u00a0=\u00a0.0239). The adverse prognostic impact of the mutations was not clear for patients treated with second-generation TKIs. The multivariate analysis affirmed that mutations in AS\/MTF genes independently serve as adverse prognostic factors for molecular response, failure-free survival, and progression risk. Additionally, there was an observable nonsignificant trend indicating a heightened risk of progression to advanced disease and worse overall survival. In conclusion, mutations in the AS\/MTF genes using smMIP-based NGS can help identify patients with a potential risk of both treatment failure and progression and may help upfront TKI selection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012127","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T21:09:27Z","timestamp":1709759367000},"page":"2361-2372","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes"],"prefix":"10.1182","volume":"8","author":[{"given":"Maria Agustina","family":"Perusini","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-8148","authenticated-orcid":false,"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehyung","family":"Kim","sequence":"additional","affiliation":[{"name":"3Department of Computer Science, University of Toronto, Toronto, ON, Canada"},{"name":"4The Donnelly Centre for Cellular and Biomolecular Research, Donnelly Centre For Cellular & Biomolecular Research, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0805","authenticated-orcid":false,"given":"Katia","family":"Pagnano","sequence":"additional","affiliation":[{"name":"5Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"6Fundaleu, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-7718","authenticated-orcid":false,"given":"Ivana","family":"Je\u017e\u00ed\u0161kov\u00e1","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane\u017eka","family":"Kvetkov\u00e1","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Jur\u010dek","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyoon","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngseok","family":"Yoo","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongyoon","family":"Yi","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"7Department of Internal Medicine, Inje University Ilsan-Paik Hospital, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyewon","family":"Lee","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"8Department of Internal Medicine, Center for Hematologic Malignancies, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ha","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"9Division of Hematology and Oncology, Department of Internal Medicine, Soon Chun Hyang University Seoul Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myunghee","family":"Chang","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"10National Health Insurance Service Ilsan Hospital, Ilsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-3633","authenticated-orcid":false,"given":"Jose-Mario","family":"Capo-Chichi","sequence":"additional","affiliation":[{"name":"11Genome Diagnostics & Cancer Cytogenetics Laboratories, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6597-4613","authenticated-orcid":false,"given":"Jessie J. F.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"12Ontario Institute for Cancer Research, Toronto, ON, Canada"},{"name":"13Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Arruda","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"14Malignant Hematology Tissue Bank, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-8816","authenticated-orcid":false,"given":"Mark","family":"Minden","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"14Malignant Hematology Tissue Bank, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"15Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolei","family":"Zhang","sequence":"additional","affiliation":[{"name":"4The Donnelly Centre for Cellular and Biomolecular Research, Donnelly Centre For Cellular & Biomolecular Research, Toronto, ON, Canada"},{"name":"13Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada"},{"name":"16Department of Computer Science, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1747-3819","authenticated-orcid":false,"given":"Sagi","family":"Abelson","sequence":"additional","affiliation":[{"name":"12Ontario Institute for Cancer Research, Toronto, ON, Canada"},{"name":"13Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong","family":"Hwan Kim","sequence":"additional","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"15Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"issue":"8","key":"2024052418454107200_bib1","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2024052418454107200_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3324\/haematol.2021.279317","article-title":"Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers","volume":"107","author":"Krishnan","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2024052418454107200_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024052418454107200_bib4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024052418454107200_bib5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2024052418454107200_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41408-022-00667-9","article-title":"Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation","volume":"12","author":"Adnan Awad","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"2024052418454107200_bib7","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Schonfeld","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2024052418454107200_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.leukres.2015.10.005","article-title":"Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"issue":"1","key":"2024052418454107200_bib9","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"key":"2024052418454107200_bib10","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"da Silva-Coelho","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"2024052418454107200_bib11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/leu.2017.17","article-title":"The clonal origins of leukemic progression of myelodysplasia","volume":"31","author":"Kim","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2024052418454107200_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet"},{"issue":"Suppl 1","key":"2024052418454107200_bib13","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2022-170069","article-title":"RAS pathway mutations are associated with progression after hypomethylating agent therapy in chronic myelomonocytic leukemia","volume":"140","author":"Montalban-Bravo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024052418454107200_bib14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024052418454107200_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2024052418454107200_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1101\/gr.147686.112","article-title":"Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation","volume":"23","author":"Hiatt","year":"2013","journal-title":"Genome Res"},{"issue":"8","key":"2024052418454107200_bib17","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/bioinformatics\/btac081","article-title":"SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data","volume":"38","author":"Medeiros","year":"2022","journal-title":"Bioinformatics"},{"issue":"1","key":"2024052418454107200_bib18","article-title":"Sequencing error profiles of Illumina sequencing instruments","volume":"3","author":"Stoler","year":"2021","journal-title":"NAR Genom Bioinform"},{"issue":"6","key":"2024052418454107200_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2024052418454107200_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2024052418454107200_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2024052418454107200_bib22","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2024052418454107200_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2024052418454107200_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"2024052418454107200_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2008.1.419","article-title":"Milestones and monitoring in patients with CML treated with imatinib","author":"Deininger","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"2024052418454107200_bib26","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024052418454107200_bib27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024052418454107200_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024052418454107200_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"issue":"24","key":"2024052418454107200_bib30","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024052418454107200_bib31","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024052418454107200_bib32","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A\u00a0phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024052418454107200_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/17512433.1.3.391","article-title":"Modeling cumulative incidence function for competing risks data","volume":"1","author":"Zhang","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"2024052418454107200_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024052418454107200_bib35","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2024052418454107200_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","article-title":"Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia","volume":"1","author":"Waanders","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2024052418454107200_bib37","first-page":"449","article-title":"Differentiation in human myeloblastic leukemia studied in cell culture","volume":"89","author":"McCulloch","year":"1977","journal-title":"Am J Pathol"},{"issue":"5","key":"2024052418454107200_bib38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.23410","article-title":"Prognostic impact of RAS mutations in patients with myelodysplastic syndrome","volume":"88","author":"Al-Kali","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"2024052418454107200_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ejh.13092","article-title":"The genetic and molecular pathogenesis of myelodysplastic syndromes","volume":"101","author":"Shallis","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"2024052418454107200_bib40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"issue":"10","key":"2024052418454107200_bib41","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/genes10100794","article-title":"Transcription factors that govern development and disease: an achilles heel in cancer","volume":"10","author":"Huilgol","year":"2019","journal-title":"Genes (Basel)"},{"issue":"1","key":"2024052418454107200_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PPO.0000000000000639","article-title":"Transcription factors and cancer: approaches to targeting","volume":"29","author":"Shiah","year":"2023","journal-title":"Cancer J"},{"issue":"1","key":"2024052418454107200_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2007.11.031","article-title":"An E2F1-dependent gene expression program that determines the balance between proliferation and cell death","volume":"13","author":"Hallstrom","year":"2008","journal-title":"Cancer Cell"},{"issue":"1","key":"2024052418454107200_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-018-0794-0","article-title":"The role of RICTOR downstream of receptor tyrosine kinase in cancers","volume":"17","author":"Jebali","year":"2018","journal-title":"Mol Cancer"},{"issue":"12","key":"2024052418454107200_bib45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024052418454107200_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/his.13500","article-title":"GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4alpha expression, and KRAS mutations","volume":"73","author":"Nakajima","year":"2018","journal-title":"Histopathology"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2361\/2226417\/blooda_adv-2023-012127-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2361\/2226417\/blooda_adv-2023-012127-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:46:17Z","timestamp":1716576377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2361\/515202\/Mutations-in-myeloid-transcription-factors-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012127","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}